Table 2 Changes in medication treatment 1 year after pharmacist consultation:
Variable | Pharmacist consultation group (N = 740) | Control group (N = 1476) | p-value |
|---|---|---|---|
Total medications at baseline N (Mean; CI) | 11.4 ± 2.4 | 9.9 ± 2.4 | < 0.001 |
Medications stopped N (Mean; SD) | 1.5 ± 1.1 | 0.7 ± 0.9 | < 0.001 |
Medications started N (Mean; SD) | 1.3 ± 0.8 | 0.4 ± 0.8 | < 0.001 |
Proportion of patients that stopped at least one medication, N (%) | 610 (82.4) | 712 (48.2) | < 0.001 |
Proportion of patients that started at least one medication, N (%) | 483 (65.2) | 373 (25.2) | < 0.001 |
Medications adherence before % (Mean; SD) | 79.3 ± 16.3 | 83.7 ± 14.3 | 0.014 |
Medications adherence after % (Mean; SD) | 81.1 ± 15.1 | 88.4 ± 11.8 | < 0.001 |
Difference in adherence % (Mean; SD) | 1.6 ± 13.6 | 4.7 ± 14.2 | 0.036 |
Patients on anxiolytics N (%) | 136 (18.4) | 377 (25.5) | < 0.001 |
Patients who stopped anxiolytics (BNZ) N (% anxiolytics users) | 80 (58.8) | 165 (43.8) | 0.029 |
Patients who started anxiolytics (BNZ) N (%) | 30 (22) | 142 (37.7) | < 0.001 |
Patients on chronic opioids 341 pts N (% opioids users) | 72 (9.7) | 269 (18.2) | < 0.001 |
Patients who stopped opioids N (%) | 36 (50.0) | 85 (31.6) | < 0.001 |
Patients who started opioids N (%) | 22 (30.6) | 114 (42.4) | 0.07 |
Diabetic patients with sulfonylureas N (%) | 112 (20.4) | 252 (23.1) | < 0.001 |
Diabetic patients who stopped sulfonylureas, N (%) | 12 (10.7) | 12 (3.6) | < 0.001 |
Diabetic patients who started Sulfonylureas, N (%) | 10 (8.9) | 35 (13.8) | < 0.001 |
Diabetic patients with GLP1 N (%) | 98 (17.9) | 160 (14.6) | 0.06 |
Diabetic patients who stopped GLP1, N (%) | 2 (2.0) | 15 (9.4) | < 0.001 |
Diabetic patients who started GLP1, N (%) | 16 (16.4) | 18 (11.2) | 0.031 |